Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $8.3 million.

  • Janux Therapeutics' Cash from Investing Activities fell 3446.43% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.6 million, marking a year-over-year decrease of 561.7%. This contributed to the annual value of -$258.0 million for FY2024, which is 52635.58% down from last year.
  • Per Janux Therapeutics' latest filing, its Cash from Investing Activities stood at $8.3 million for Q3 2025, which was down 3446.43% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Cash from Investing Activities peaked at $33.9 million during Q4 2024, and registered a low of -$340.4 million during Q1 2025.
  • Over the past 5 years, Janux Therapeutics' median Cash from Investing Activities value was $1.6 million (recorded in 2025), while the average stood at -$48.0 million.
  • In the last 5 years, Janux Therapeutics' Cash from Investing Activities skyrocketed by 2040588.24% in 2022 and then crashed by 120132.72% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Cash from Investing Activities stood at $7.3 million in 2021, then plummeted by 121.89% to -$1.6 million in 2022, then soared by 793.45% to $11.1 million in 2023, then soared by 205.01% to $33.9 million in 2024, then plummeted by 75.52% to $8.3 million in 2025.
  • Its Cash from Investing Activities was $8.3 million in Q3 2025, compared to $1.6 million in Q2 2025 and -$340.4 million in Q1 2025.